(Q45262881)

English

Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis--the TOPIC study: a randomised controlled trial

scientific article published in February 2005

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

11 December 2017

Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis--the TOPIC study: a randomised controlled trial (English)

1 reference

Europe PubMed Central

11 December 2017

cystic fibrosis

0 references

1

1 reference

Europe PubMed Central

11 December 2017

author name string

Kelvin H-V Tan

2

1 reference

Europe PubMed Central

11 December 2017

Pauline Hyman-Taylor

3

1 reference

Europe PubMed Central

11 December 2017

Michael Mulheran

4

1 reference

Europe PubMed Central

11 December 2017

Sarah Lewis

5

1 reference

Europe PubMed Central

11 December 2017

David Stableforth

6

1 reference

Europe PubMed Central

11 December 2017

Alan Prof Knox

7

1 reference

Europe PubMed Central

11 December 2017

TOPIC Study Group

8

1 reference

Europe PubMed Central

11 December 2017

language of work or name

0 references

publication date

1 February 2005

1 reference

Europe PubMed Central

11 December 2017

1 reference

Europe PubMed Central

11 December 2017

365

1 reference

Europe PubMed Central

11 December 2017

9459

1 reference

Europe PubMed Central

11 December 2017

573-578

1 reference

Europe PubMed Central

11 December 2017

Lack of concordance in the use and monitoring of intravenous aminoglycosides in UK cystic fibrosis centers.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917906-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Alternative dosing strategy for aminoglycosides: impact on efficacy, nephrotoxicity, and ototoxicity.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917906-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Aminoglycoside Prescribing and Surveillance in Cystic Fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917906-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Adaptive resistance to tobramycin in Pseudomonas aeruginosa lung infection in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917906-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical pharmacokinetics of antimicrobial drugs in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917906-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917906-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917906-9

7 January 2021

based on heuristic

inferred from DOI database lookup

MW/Pharm, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917906-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Trials to assess equivalence: the importance of rigorous methods

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917906-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Once-daily tobramycin in the treatment of adult patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917906-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy, tolerance, and pharmacokinetics of once daily tobramycin for pseudomonas exacerbations in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917906-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Renal function in cystic fibrosis: proteinuria and enzymuria before and after tobramycin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917906-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Acute renal failure and cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917906-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Antibiotics and Acute Renal Failure in Children with Cystic Fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917906-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Spread of beta-lactam-resistant Pseudomonas aeruginosa in a cystic fibrosis clinic.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917906-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Continuous infusion of ceftazidime with a portable pump is as effective as thrice-a-day bolus in cystic fibrosis children

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917906-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(05)17906-9

1 reference

Europe PubMed Central

11 December 2017

1 reference

Europe PubMed Central

11 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45262881&oldid=2071890660"